Difference between revisions of "Dacarbazine (DTIC)"

Revision as of 00:44, 11 April 2018

General information

Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.^[1]^[2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

5/27/1975: Initial FDA approval

Also known as

Generic names: dacarbazin, imidazole carboxamide
Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac

References

[insert-1] 1.0 ^1.1 Dacarbazine (DTIC) package insert

[2] Dacarbazine (DTIC) package insert (locally hosted backup)

[3] Dacarbazine (DTIC) patient drug information (Chemocare)

[4] Dacarbazine (DTIC) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 32: / Line 32: @@
 [[Category:Alkylating agents]]
+[[Category:Triazenes]]
 [[Category:DNA synthesis inhibitors]]
 [[Category:Antimetabolites]]